BioWorld Science

July 21, 2022

View Archived Issues

p62 is required to eliminate pathological oligomeric tau species in a mouse model of tauopathy

Dapl1 identified as novel target for cancer immunotherapy

Incyte patents new JAK2 inhibitors

Korea Institute of Science and Technology divulges TGF-beta inhibitors

Wuhan Yuxiang Pharmaceutical Technology identifies SOS1/KRAS interaction inhibitors

Janssen Pharmaceutica synthesizes new CDK7 inhibitors

Hong Kong Baptist University divulges new antiviral compounds

Biallelic variants in RASGRP2 gene tied to bleeding diathesis

Health Canada clears QBKPN to enter clinic to restore innate immunity in elderly

Qu Biologics has received clearance from Health Canada to proceed with a randomized, placebo-controlled trial of QBKPN, a first-in-class innate immune modulator that enhances lung immunity, in the elderly. Read More

SMIM1 gene loss-of-function variant found to increase the risk of stroke

Identification of novel vanin-1 inhibitors

SARS-CoV-2 infection of neurons; no ACE2 required

Today's news in brief

BioWorld

BioWorld briefs for June 3, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...